Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression

AS Korganow, AM Knapp, H Nehme-Schuster… - Journal of …, 2010 - Elsevier
AS Korganow, AM Knapp, H Nehme-Schuster, P Soulas-Sprauel, V Poindron, JL Pasquali…
Journal of autoimmunity, 2010Elsevier
B lymphocytes from patients with systemic lupus erythematosus (SLE) are hyperactive and
produce autoantibodies. Several B cell phenotype characteristics such as the expansion of
activated populations, and of a newly identified memory compartment have already been
reported. These results are not easy to interpret because of the clinical heterogeneity of SLE,
as well as the difficulties to establish homogeneous and well defined groups taking in
consideration the activity of the disease and the various therapies. However, although many …
B lymphocytes from patients with systemic lupus erythematosus (SLE) are hyperactive and produce autoantibodies. Several B cell phenotype characteristics such as the expansion of activated populations, and of a newly identified memory compartment have already been reported. These results are not easy to interpret because of the clinical heterogeneity of SLE, as well as the difficulties to establish homogeneous and well defined groups taking in consideration the activity of the disease and the various therapies. However, although many mediators and mechanisms can contribute to the clinical presentation and subsequent progression of individuals with SLE, several data suggest that some intrinsic B cells abnormalities may be central to the disease process. In this view, we have analysed the phenotype of B cells from 18 patients with quiescent diseases (mean SLEDAI score below 2) and from 11 healthy controls. B cell surface marker expression was determined by flow cytometry. We analysed the main B cell sub-populations. We demonstrate the persistence of plasmocyte-differentiated and -activated B cells even in quiescent patients. However, quiescent patients display a decrease in memory B cells that could reflect the control of their disease. Above all, we describe a lower membrane expression of the CD19 protein on all B cells in every patient compared to controls. This lower CD19 expression is associated with reduced CD45 levels. It is not associated with an evident gene expression alteration and in vitro stimulation restores a control phenotype. These findings suggest certain mechanisms of lupus development.
Elsevier